The GLP is committed to full transparency. Download and review our 2019 Annual Report

depression

Pharmacogenetics and depression: Genetic screening could eliminate trial-and-error approach to medications

Antidepressants may soon be added to the growing list of medications genetically matched to patients most likely to respond — ...
pharmacogenetics

FDA approves 23andMe’s direct-to-consumer DNA test assessing patient’s ability to respond to antidepressants

The U.S. Food and Drug Administration (FDA) announced [October 31] that it has approved the marketing of 23andMe’s reports on ...
dna pharmaceutical drug

Genetic data share: 23andMe partners with drugmaker GlaxoSmithKline

23andMe customers might just play a role in helping create one of Big Pharma’s next blockbuster drugs. On [July 25, ...